Dublin, Sept. 11, 2023 (GLOBE NEWSWIRE) -- The "Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global methicillin-resistant staphylococcus aureus drugs market is expected to grow from $2.15 billion in 2022 to $2.26 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The methicillin-resistant staphylococcus aureus drugs market is expected to reach $2.73 billion in 2027 at a CAGR of 4.8%.
The main types of methicillin-resistant Staphylococcus aureus (MRSA) drugs are lipopeptides, oxazolidinones, cephalosporins, tetracyclines, folate antagonists, lipoglycopeptides, and others. Lipopeptides are a class of antibiotics that contain both lipid and peptide components and exhibit therapeutic intervention by disrupting the bacterial cell membrane, leading to membrane depolarization and inhibition of cell wall synthesis.
Various types of indications include skin infections, bone and joint infections, bacteremia, and animal infections. The several types of methicillin-resistant Staphylococcus aureus (MRSA) involved are hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). These drugs are administered by oral and parenteral routes of administration and are used by various end users, such as hospitals and clinics, research and academic institutes, and others.
The methicillin-resistant staphylococcus aureus drugs market research report provides methicillin-resistant staphylococcus aureus drugs market statistics, including methicillin-resistant staphylococcus aureus drugs industry global market size, regional shares, competitors with a methicillin-resistant staphylococcus aureus drugs market share, detailed methicillin-resistant staphylococcus aureus drugs market segments, market trends and opportunities, and any further data you may need to thrive in the methicillin-resistant staphylococcus aureus drugs industry.
Product innovation is the key trend gaining popularity in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market. Major companies involved in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focused on innovating new products to improve their observation power and sustain their position in the market.
For instance, in March 2021, Melinta Therapeutics LLC, a US-based biopharmaceutical firm, announced the FDA approval of Kimyrsa (oritavancin), indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
Kimyra is the first oritavancin one-hour infusion product prepared from one 1,200 mg vial and is compatible with both 0.9% sodium chloride injection (NS) and 5% dextrose in sterile water (D5W). The drug acts by inhibiting transpeptidation, inhibiting transglycosylation, and disrupting cell membrane integrity.
North America was the largest region in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in methicillin-resistant Staphylococcus aureus (MRSA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the methicillin-resistant Staphylococcus aureus (MRSA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is expected to propel the growth of the methicillin-resistant Staphylococcus aureus drugs market going forward. A methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by Staphylococcus bacteria that is resistant to some antibiotics used for treating ordinary staph infections. MRSA infections must be treated with drugs that destroy and inhibit the growth of MRSA bacteria in humans and animals.
For instance, in November 2022, according to the Centers for Disease Control and Prevention, a US-based health agency under the Department of Health and Human Services, hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections increased by 14% from 2020 to 2021.
Further, in December 2022, according to a report by Statens Serum Institute, a Denmark-based sector research institute on MRSA - disease prevalence, in 2021, the number of community-acquired infections with recorded contact with a hospital or the nursing sector in the previous six months was 181, up from 159 in 2020. Therefore, the increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is driving the growth of the methicillin-resistant Staphylococcus aureus drug market.
The methicillin-resistant Staphylococcus aureus (MRSA) drug market consists of sales of vancomycin, daptomycin, linezolid, ceftaroline, tedizolid, and clindamycin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $2.26 billion |
| Forecasted Market Value (USD) by 2027 | $2.73 billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
Major players in the methicillin-resistant staphylococcus aureus (MRSA) drugs market are
- Basilea Pharmaceutica Ltd.
- Merck & Co Inc.
- Pfizer Inc.
- Theravance Biopharma Inc.
- Allergan PLC
- Cumberland Pharmaceuticals Inc.
- Debiopharm International S.A.
- The Medicines Company
- AbbVie Inc.
- Innovation Pharmaceuticals Inc.
- Melinta Therapeutics Inc.
- Nabriva Therapeutics Plc.
- Paratek Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Absynth Biologics
- AmpliPhi Biosciences Corporation
- AstraZeneca PLC
Key Topics Covered:
1. Executive Summary
2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics
3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies
4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Macro Economic Scenario
4.1. COVID-19 Impact On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
4.2. Ukraine-Russia War Impact On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
4.3. Impact Of High Inflation On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
5. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size And Growth
5.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation
6.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Lipopeptides
- Oxazolidinones
- Cephalosporin
- Tetracycline
- Folate Antagonist
- Lipoglycopeptide
- Other Drug Classes
6.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Skin Infections
- Bone and Joint Infections
- Bacteremia
- Animal Infections
6.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospital-Acquired (HA-MRSA)
- Community-Acquired (CA-MRSA)
6.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Oral Administration
- Parenteral Administration
6.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals and Clinics
- Research and Academic Institutes
- Other End-Users
7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Regional And Country Analysis
7.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/dgfjo9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
